Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24340294 | 0.89 | HDAC6 (0.37) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL23620130 | 0.87 | HDAC6 (0.34) | HDAC6L3MBTL1CA14 | |
| SCHEMBL4149715 | 0.86 | ALDH1A1 (0.42) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL30304345 | 0.86 | ALDH1A1 (0.42) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL30304722 | 0.86 | ALDH1A1 (0.42) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL15645124 | 0.85 | CA14 (0.44) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL361154 | 0.83 | HDAC6 (0.38) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL3752709 | 0.82 | HDAC6 (0.40) | HDAC6CA14HDAC1HDAC2DGAT1 | |
| SCHEMBL4683655 | 0.81 | HDAC6 (0.37) | HDAC6L3MBTL1CA14HDAC1HDAC2 | |
| SCHEMBL21424988 | 0.81 | HDAC6 (0.37) | HDAC6L3MBTL1CA14HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| US-8039430-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-10-18 | — | — | US | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| EP-1836159-A4 | PEPTIDIC COMPOUNDS | UNIV WOLLONGONG (AU) | 2009-02-25 | — | — | EP | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| US-20080300287-A1 | Peptidic Compounds | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-04 | — | — | US | disclosed |
| EP-1836159-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300287-A1 | Peptidic Compounds | VIP, NGLY1, FURIN | HDAC6 512/4885L3MBTL1 3820/4885CA14 2294/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | HDAC6 1199/4885L3MBTL1 853/4885CA14 1886/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | HDAC6 445/4885L3MBTL1 3778/4885CA14 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.